The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy, but risk is elevated in the first year of treatment, according to a ...

Objective: To review drug interaction studies of glucagon-like peptide-1 receptor agonists (GLP-1RAs) and concurrent oral medications. Data Sources: PubMed was searched (to December 5, 2011 ...

With respect to risks, GLP-1RA use was significantly associated with an increased risk of gastrointestinal disorders, hypotension, syncope, arthritic disorders, drug-induced pancreatitis, and other ...

Glucagon-like peptide-1 receptor agonists (GLP-1 RA) significantly reduce the risk for clinically meaningful chronic kidney disease (CKD) progression and major adverse cardiovascular events (MACE) in ...

For people with diabetes, the use of GLP-1 RAs is associated with a reduced risk for certain disorders and conditions, including neurocognitive and cardiometabolic disorders, and with an increased ...

(HealthDay News) — Glucagon-like peptide 1 receptor agonist (GLP-1 RA ... and clinicians about the short-term safety of these drugs,” the authors write. “Nevertheless, evidence was ...

A study on GLP1RA medications found that behavioral side effects likely do not result from direct action on GLP1R.

Websites that sell compounded glucagon-like peptide-1 receptor agonists often partially inform or misinform consumers.

Josh Gad says he's taking 'life-changing' GLP-1 medication for weight loss but admits that it can't replace having a healthy ...

Scouted selects products independently. If you purchase something from our posts, we may earn a small commission. Unless you ...

Weight loss drugs like Ozempic and Wegovy have been tied in a large, national study to a drop in the risk of developing ...

Explore how GLP-1 agonists, originally for diabetes, could transform addiction treatment by reducing cravings.